Audit: QRS - Tocotrienols for Health & Longevity
Audit conducted on 11/01/2026 09:41 using AI4L / Opus 5.5
Summary
| Items | Count |
|---|---|
| Total | 97 |
| Passed | 87 |
| Failed | 0 |
| N/A | 10 |
| Pass Rate | 100.00% |
- Total = Passed + Failed + N/A
- Pass Rate = Passed / (Passed + Failed) × 100
- N/A items are excluded from the pass rate calculation
1. General Rules
| # | Description | Result | Comments |
|---|---|---|---|
| 1.1 | Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER. | 🟢 | Lede (l.439), Protocol (l.450-478), Time to effect (l.489-517), tiers (l.531-537, 595-601), gates (l.548-578), Monitoring (l.620-688) and Qualitative (l.697-712) all trace to ER text (Conclusion, Therapeutic Protocol, Practical Considerations, Key Interactions, Monitoring) |
| 1.2 | Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing. | 🟢 | Hedges kept: “possible bleeding tendency” (l.559), “no study links time of day to effect” (l.478), “Only at 2 years” (l.514), “No established target” (l.656, 678); theoretical items sit under the template sub-heading |
| 1.3 | The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”). | 🟢 | No strengthening or softening found; lede keeps “modest”, “has not held up”, “few at studied doses” |
| 1.4 | The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc. | 🟢 | Contraindications from “Populations who should avoid”, interactions from Documented/Theoretical lists, risks from Potential Risks; no modifying factor relabelled |
| 1.5 | PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact. | 🟢 | No PMIDs, citations, expert names, NCT IDs or brand names in the QRS |
2. Focus, Tone & Audience
| # | Description | Result | Comments |
|---|---|---|---|
| 2.1 | The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing. | 🟢 | Cautious, evidence-weighted tone of the ER Conclusion carried into the lede |
| 2.2 | The tone of the QRS is expert, accessible, objective, and data-driven | 🟢 | |
| 2.3 | The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor | 🟢 | |
| 2.4 | The QRS avoids language that implies medical or clinical advice | 🟢 | No imperative or advisory wording |
| 2.5 | The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising” | 🟢 | |
| 2.6 | The QRS never addresses the reader directly — it presents evidence, not guidance | 🟢 | No “you”/”your” or imperatives addressed to the reader |
| 2.7 | The QRS is written in plain language, avoiding unnecessary medical jargon | 🟢 | Technical terms (HbA1c, eGFR, INR, sulfonylureas, cyclosporine) are ER labels/marker names carried verbatim |
| 2.8 | Information is presented in a concise and very compact manner | 🟢 | |
| 2.9 | The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review. | 🟢 | |
| 2.10 | The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort. | 🟢 | |
| 2.11 | The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort. | 🟢 | |
| 2.12 | Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience. | 🟢 | Lede frames use for healthy longevity and flags industry-linked, unreplicated evidence |
| 2.13 | The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim. | 🟢 | No “anti-aging” in the document |
| 2.14 | The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “oral” / “administered orally” not “taken by mouth” / “given by mouth”; “injection” not “shot”; “adverse event” not “bad reaction”). This holds on EVERY surface, including the QRS lede — the stricter plain-language bar (see 2.7) does not license lay phrasing for route of administration. Direct quotes from sources are exempt. | 🟢 | No colloquial route or consumer-grade terms (pill, shot, taken by mouth) |
3. Template Integrity
| # | Description | Result | Comments |
|---|---|---|---|
| 3.1 | The following labels and headings on the QRS are fixed and not modified: • Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment” • Gate headings: “Contraindications”, “Key Interactions” • Tier labels: “High”, “Medium”, “Low”, “Speculative” • Table column headers in Monitoring: “Marker”, “Target”, “Why” |
🟢 | All fixed headings, gate headings, tier labels and column headers unchanged |
| 3.2 | Every element carrying a data-qrs-var attribute in [qrs_template] is present in the QRS with the same name | 🟢 | All template data-qrs-var names present; # rows expanded to marker_1-6 and qualitative_item_1-6 |
| 3.3 | Everything outside the data-qrs-var spans — markup, text, styles, comments — is as in the template; spans that no checklist item addresses are left unchanged as well | 🟢 | Diff vs template shows changes only inside data-qrs-var spans, the required display:none on benefits_high/risks_high, and the filled metadata block |
4. Formatting
| # | Description | Result | Comments |
|---|---|---|---|
| 4.1 | An empty ER section never produces visible empty-state text in the QRS: the corresponding region is hidden or left empty. Phrases such as “None documented in human trials to date” or “Not formally studied” appear only where the ER uses them for a fact the QRS carries over. | 🟢 | Empty High tiers hidden (l.527, 591); “Not specified in the ER” (l.645) is the wording 14.3 requires |
| 4.2 | Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label. | 🟢 | Interaction, contraindication, protocol and qualitative labels use the ER bold labels |
| 4.3 | Labels are not paraphrased, abbreviated, or invented. | 🟢 | Labels only trimmed of example names or glosses (e.g., “simvastatin”, “rivaroxaban”, NSAIDs gloss); kept words are the ER’s own |
| 4.4 | The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels. | 🟢 | No emoji indicators |
| 4.5 | The QRS is designed to render on one A4 page. It fails this item only for one of four things: a trailing clause after a dash, an optional gloss, an example list left untrimmed, or a repetition. Nothing else is cut to fit. | 🟢 | No trailing dash clauses, untrimmed example lists, optional glosses or repetitions |
5. Metadata
| # | Description | Result | Comments |
|---|---|---|---|
| 5.1 | The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content. | 🟢 | Metadata comment directly follows <!doctype html> (l.2) |
| 5.2 | Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML. | 🟢 | YAML delimited by — (l.3, 13) |
| 5.3 | The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet. | 🟢 | |
| 5.4 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | Values trimmed; only duration quoted (contains a colon) |
| 5.5 | The filename of the source ER is stated as “er_filename: [er_filename]” | 🟢 | er_filename: tocotrienols_2026-1101-0413_Opus_ER.md |
| 5.6 | Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]” | 🟢 | qrs_prompt_version: 26.10.25 matches QRS.md |
| 5.7 | Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430) | 🟢 | qrs_creation_date: 2026-1101-0908 |
| 5.8 | The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]” | 🟢 | qrs_creator_ai_nickname: Opus |
| 5.9 | The nickname of the AI is the full name without the version number, with all remaining words joined by hyphens (e.g., Opus, Sonnet, Grok, Gemini-Flash, GPT); when the full name has no version number or is “Unknown”, the nickname equals the full name | 🟢 | |
| 5.10 | The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]” | 🟢 | qrs_creator_ai_fullname: Opus 5.5 |
| 5.11 | The full name of the AI consists of the model name (the word or words directly before the version number, leaving out the first if there is more than one, e.g., Claude Opus 5.5 → Opus 5.5), the model version number and the variant (if any) as stated in the system prompt or developer instructions of the creating model, with every word capitalized and without product, effort or pricing names (e.g., Opus X.Y, Sonnet X.Y, Grok X.Y, Gemini X.Y Flash, GPT X.Y), the model name alone when the system prompt or developer instructions name a model without a version number (e.g., Grok), or “Unknown” when neither the system prompt nor the developer instructions of the creating model name a model | 🟢 | |
| 5.12 | The filename of the document is stated as “qrs_filename: [filename of this document]” | 🟢 | qrs_filename matches the file name |
6. Page Title & Header
| # | Description | Result | Comments |
|---|---|---|---|
| 6.1 | [page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &) |
🟢 | “Tocotrienols for Health & Longevity - Quick Reference Sheet” (l.21) |
| 6.2 | [header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &) |
🟢 | l.423 |
| 6.3 | [header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY] | 🟢 | 11/01/2026 from 2026-1101-0908 (l.427) |
| 6.4 | [header_subline_model] is set to [qrs_creator_ai_fullname] | 🟢 | Opus 5.5 (l.431) |
| 6.5 | No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker. | 🟢 |
7. At-A-Glance Section
| # | Description | Result | Comments |
|---|---|---|---|
| 7.1 | [at_a_glance] opens by saying what the intervention is — its kind (e.g., dietary supplement, prescription medication, peptide, plant, procedure, practice) — and what it is used for, in plain language, before any verdict on the evidence | 🟢 | Opens “a less-studied form of vitamin E sold as palm-oil, rice-bran or annatto supplements for healthy longevity” (l.439) |
| 7.2 | [at_a_glance] is dense, execution-oriented summary of the ER Conclusion section |
🟢 | Condenses all three Conclusion paragraphs |
| 7.3 | [at_a_glance] is no longer than 70 words | 🟢 | Exactly 70 words (script count) |
| 7.4 | Every fact in [at_a_glance] is supported by a distinct passage in the ER. | 🟢 | Each fact maps to a distinct Conclusion sentence |
| 7.5 | It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead | 🟢 | No acronyms; plain terms (“clot-preventing drugs”, “diabetes-related kidney disease”) |
| 7.6 | It DOES NOT cite specific trials (names, years, sample sizes, p-values) | 🟢 | |
| 7.7 | It DOES NOT cite effect sizes, relative risks, or statistical results | 🟢 |
8. Contraindications
| # | Description | Result | Comments |
|---|---|---|---|
| 8.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | |
| 8.2 | [stop_items] represent the Contraindications from the ER | 🟢 | All three “Populations who should avoid” items (l.548-550) |
| 8.3 | Individual [stop_items] are formatted as <li></li> | 🟢 | |
| 8.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | Labels only; rationale stripped |
| 8.5 | Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | “(for annatto-derived products)” kept (l.548) |
| 8.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | ER uses no ranking notation in contraindications |
| 8.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision. |
🟢 | Section populated; ER names populations to avoid |
| 8.8 | If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. | N/A | Section not empty |
9. Key Interactions
| # | Description | Result | Comments |
|---|---|---|---|
| 9.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | |
| 9.2 | [caution_items] represent the ER’s documented interactions — the items under its “Documented interactions:” label — excluding any that are already listed as Contraindications and any entry phrased as no interaction found | 🟢 | Statins, aspirin plus clopidogrel, oral glucose-lowering drugs, food; chemotherapy and tamoxifen (no interaction found) correctly excluded |
| 9.3 | [caution_theoretical_items] represent the ER’s theoretical interactions — the items under its “Theoretical interactions (inferred from mechanism, not studied in humans):” label | 🟢 | All eight theoretical items present (l.571-578) |
| 9.4 | The ER placeholder “None identified” is never an item: it means that group is empty | 🟢 | No “None identified” item |
| 9.5 | Individual [caution_items] and [caution_theoretical_items] are formatted as <li></li>. The template’s bold “Theoretical (inferred from mechanism)” sub-heading is the only marker of the second list’s status: no item carries “(theoretical)”, “inferred from” or a mechanism clause | 🟢 | No “(theoretical)” or mechanism clauses on items |
| 9.6 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | Only ER consequence phrases kept; mitigations and study details stripped |
| 9.7 | Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | Example drug lists and “(400 IU or more)” preserved, trimmed |
| 9.8 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | ER uses no ranking notation in interactions |
| 9.9 | If the ER’s theoretical group is empty, the whole Theoretical block — the caution_theoretical span with its sub-heading and list — is hidden with style="display:none", not removed: its spans stay in place, empty. |
N/A | ER theoretical group is not empty |
| 9.10 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used. |
🟢 | Section populated; ER names interactions |
| 9.11 | If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on, and the Theoretical block is hidden per 9.9. E.g. | N/A | Section not empty |
10. Protocol
| # | Description | Result | Comments |
|---|---|---|---|
| 10.1 | The section is derived from the ER Therapeutic Protocol section |
🟢 | |
| 10.2 | The three sets of [action] items cover the three most important actionable implementation aspects from that section | 🟢 | Palm regimen, annatto regimen and fed dosing (l.450-478) |
| 10.3 | If fewer than three distinct actionable implementation aspects are mentioned in the ER, the unused sets are left empty and hidden with style="display:none", not filled with placeholder text or empty-state phrasing. |
N/A | ER gives three or more actionable aspects |
| 10.4 | All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from that section. | 🟢 |
11. Time to Effect
| # | Description | Result | Comments |
|---|---|---|---|
| 11.1 | The three sets of [time] items cover the three most important time-to-effect aspects from the ER | 🟢 | Liver enzymes, kidney function, white matter from Practical Considerations |
| 11.2 | The sets are picked and ordered by the magnitude of the related benefit | 🟢 | Ordered with the ER’s most consistent findings (liver, kidney) first, then white matter |
| 11.3 | If fewer than three distinct time-to-effect aspects are mentioned in the ER, the unused sets are left empty and hidden with style="display:none", not filled with placeholder text or empty-state phrasing. |
N/A | ER gives more than three time-to-effect aspects |
| 11.4 | All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER. | 🟢 | |
| 11.5 | If the ER provides no information on time to effect at all, the whole Time to effect block (its subhead and all three sets) is hidden with style="display:none", not removed: its spans stay in place, empty. |
N/A | ER provides time-to-effect information |
12. Benefits
| # | Description | Result | Comments |
|---|---|---|---|
| 12.1 | The section is derived from the ER Expected Benefits section |
🟢 | |
| 12.2 | Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative] | 🟢 | |
| 12.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Headings only, no magnitudes or qualifiers |
| 12.4 | Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | No parenthetical content |
| 12.5 | If a tier (high, medium, low, speculative) has no items, its span is hidden with style="display:none", not filled with “None documented in human trials to date” or similar empty-state phrasing. |
🟢 | Empty High tier hidden (l.527) |
13. Risks
| # | Description | Result | Comments |
|---|---|---|---|
| 13.1 | The section is derived from the ER Potential Risks & Side Effects section |
🟢 | |
| 13.2 | Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative] | 🟢 | |
| 13.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | |
| 13.4 | Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | |
| 13.5 | If a tier (high, medium, low, speculative) has no items, its span is hidden with style="display:none", not filled with “None documented in human trials to date” or similar empty-state phrasing. |
🟢 | Empty High tier hidden (l.591) |
14. Monitoring
| # | Description | Result | Comments |
|---|---|---|---|
| 14.1 | The section is derived from the ER Monitoring Protocol & Defining Success section |
🟢 | |
| 14.2 | All measurable/quantifiable biomarkers from that section are listed, one table row per marker; the template’s # row is the pattern, repeated with # replaced by 1, 2, 3 … in the data-qrs-var names |
🟢 | All five ER table markers plus fasting glucose (named in the HbA1c row) listed, rows numbered 1-6 |
| 14.3 | [marker_#name] is the marker, [marker#target] its target value or range as given in the ER, [marker#_why] its purpose in a few words; a target the ER does not give is written “Not specified in the ER” | 🟢 | Targets match the ER; fasting glucose target “Not specified in the ER” |
| 14.4 | [monitoring_cadence] is populated with the monitoring cadence/frequency derived from that section. It is not left with placeholder text or empty. | 🟢 | Cadence matches ER baseline and ongoing monitoring (l.688) |
| 14.5 | If the ER names no measurable biomarker, the table is hidden with style="display:none" and the single # row is left as in the template |
N/A | ER names measurable biomarkers |
15. Qualitative Assessment
| # | Description | Result | Comments |
|---|---|---|---|
| 15.1 | The section is derived from the ER Monitoring Protocol & Defining Success section |
🟢 | |
| 15.2 | All subjective/qualitative markers from that section are listed, one <li> per marker; the template’s # item is the pattern, repeated with # replaced by 1, 2, 3 … |
🟢 | All six ER qualitative markers, one <li> each (l.697-712) |
| 15.3 | If the ER names no qualitative marker, the card’s list is hidden with style="display:none" and the single # item is left as in the template |
N/A | ER names qualitative markers |
Issues 11/01/2026 09:41
Pass rate 100.00%. No issues found.
Issues 11/01/2026 09:36
- 1.2 / 1.3 — Hedge dropped on side effects: The At a Glance text at QRS line 439 says “Side effects are few at studied doses”, dropping the ER’s “Reported” (“Reported side effects are few at studied doses”, ER line 490) and so strengthening the safety claim.
Fixes 11/01/2026 09:36
- 1.2 / 1.3 — Hedge restored on side effects: In At a Glance, changed “Side effects are few at studied doses” to the ER’s “Reported side effects are few at studied doses”; changed “show possible modest benefits” to “suggest modest benefits” to keep the lede at 70 words while keeping the hedge.
Issues 11/01/2026 09:34
- 7.5 — Research jargon in lede: The At-A-Glance text at line 439 says “show modest benefit signals”; “signals” in this research sense is not a word a non-specialist would use unprompted.
Fixes 11/01/2026 09:34
- 7.5 — Research jargon in lede: Changed “show modest benefit signals” to “show possible modest benefits” in the At-A-Glance text, keeping the tentative framing and the 70-word limit.
Issues 11/01/2026 09:30
- 7.2 — Lede omits main concerns: The at-a-glance text (line 439) stops at “Reported side effects are few at studied doses” and leaves out the ER Conclusion’s main concerns (more infections in one diabetes trial, stronger anti-clotting effect with clot-preventing drugs).
Fixes 11/01/2026 09:30
- 7.2 — Lede omits main concerns: Rewrote the at-a-glance text within 70 words, condensing the benefit clause and replacing “Reported side effects are few at studied doses.” with “Side effects are few at studied doses; concerns include more infections in one trial and stronger anti-clotting effects with clot-preventing drugs.”
Issues 11/01/2026 09:26
- 14.2 — Fasting glucose row missing: The ER monitoring table pairs HbA1c with fasting glucose (ER line 456: “pair with fasting glucose”), but the QRS Monitoring table (lines 617-673) has no fasting-glucose row.
Fixes 11/01/2026 09:26
-
14.2 — Fasting glucose row added: Added a Monitoring row “Fasting glucose Not specified in the ER Paired with HbA1c in type 2 diabetes” after HbA1c and renumbered the following markers to marker_4–marker_6.
Issues 11/01/2026 09:24
- 4.5 — Time-to-effect sub repetition: time_1_sub “Liver-enzyme changes in fatty liver” (line 495) restates the label “Liver enzymes”, and time_2_sub “Kidney changes in diabetic kidney disease” (line 506) restates the label “Kidney function”.
- 7.5 — Research-register wording in lede: The At a Glance text (line 439) says “show modest, condition-specific signals”, research-register terms a non-specialist would not use unprompted or know the exact meaning of.
Fixes 11/01/2026 09:24
- 4.5 — Time-to-effect sub repetition: Changed time_1_sub from “Liver-enzyme changes in fatty liver” to “In fatty liver” and time_2_sub from “Kidney changes in diabetic kidney disease” to “In diabetic kidney disease”, so the subs no longer restate their labels.
- 7.5 — Research-register wording in lede: Replaced “show modest, condition-specific signals” with “show modest signs of benefit in some conditions”, and shortened “sold as dietary supplements from palm oil, rice bran or annatto” to “sold as palm-oil, rice-bran or annatto supplements” to stay within 70 words.
Issues 11/01/2026 09:20
- 1.1 / 7.4 — Unrepeated overstates ER wording: At-A-Glance (line 439) says “Memory, vaccine and brain findings remain unrepeated”, while the ER Conclusion says only that “none has been repeated by another group” (the vaccine signal rests on two same-group trials).
Fixes 11/01/2026 09:20
- 1.1 / 7.4 — Unrepeated overstates ER wording: Changed “remain unrepeated” to “remain unrepeated by other groups” in At-A-Glance to match the ER Conclusion; trimmed “sold as a dietary supplement … to support” to “sold as dietary supplements … for” to stay within 70 words.
Issues 11/01/2026 09:17
- 1.3 — Lede strengthens “signals”: At a Glance (line 439) says tocotrienols “show modest, condition-specific effects”, while the ER Conclusion says the evidence “points to modest, condition-specific signals rather than broad effects”.
- 4.5 — Time-to-effect repetition: Time set 3 (lines 511-517) sub “White-matter differences only at 2 years” repeats the label “Brain white matter” and the value “2 years”.
Fixes 11/01/2026 09:17
- 1.3 — Lede strengthens “signals”: Changed “show modest, condition-specific effects” to “show modest, condition-specific signals” in At a Glance, matching the ER Conclusion.
- 4.5 — Time-to-effect repetition: Changed time_3_value from “2 years” to “Only at 2 years” and time_3_sub from “White-matter differences only at 2 years” to “Lesion growth in adults with vascular risk factors” (ER Gopalan 2014 population).
Issues 11/01/2026 09:13
- 1.2 / 1.3 — Lede drops “Reported” hedge: At a Glance (line 439) states “Side effects are few at studied doses” where the ER Conclusion says “Reported side effects are few at studied doses”, stripping the hedge and strengthening the claim.
- 4.5 — Untrimmed example lists, repetition: Key Interactions keep full example lists for Statins (line 558), Anticoagulants (line 571), Antiplatelet supplements (line 576) and Lipid-lowering supplements (line 577); the cadence (line 677) lists the same markers twice and mentions warfarin INR twice.
- 7.5 — Research-register “signals” in lede: At a Glance (line 439) uses “condition-specific signals” and “Memory, vaccine and brain signals”, a research term a non-specialist would not use for study findings.
Fixes 11/01/2026 09:13
- 1.2 / 1.3 — Restored “Reported” hedge: Changed the lede’s “Side effects are few at studied doses” to the ER’s “Reported side effects are few at studied doses”.
- 4.5 — Trimmed example lists, repetition: Trimmed the Statins, Anticoagulants, Antiplatelet supplements and Lipid-lowering supplements example lists to two ER examples each, and rewrote the cadence so each marker and the warfarin INR check appears once.
- 7.5 — Replaced “signals” in lede: Changed “condition-specific signals” to “condition-specific effects” and “brain signals” to “brain findings”; dropped “and taken” to keep the lede within 70 words.
Issues 11/01/2026 09:11
- 4.5 — Optional gloss in label: The theoretical interaction label at line 572 keeps the gloss “non-steroidal anti-inflammatory drugs:” inside “NSAIDs (non-steroidal anti-inflammatory drugs: ibuprofen, naproxen)”, an optional gloss not cut for the one-page budget.
Fixes 11/01/2026 09:11
- 4.5 — Optional gloss in label: Trimmed the theoretical interaction label at line 572 from “NSAIDs (non-steroidal anti-inflammatory drugs: ibuprofen, naproxen) and over-the-counter aspirin” to “NSAIDs (ibuprofen, naproxen) and over-the-counter aspirin”.